Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
WuXi AppTec
WuXi AppTec Posts Stellar Q3 2022 Results with 209% Profit Surge
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...
WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production
WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...
Pica Partners with BrainCo to Launch ADHD Product in China
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with...
WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake
China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...